NHE1 activities and phosphorylation as well as sensitivities to NHE1 inhibitor and knockdown were more pronounced in primary samples and AML cell lines with gain-of-function kinase mutations. This evidence concerns the gene SLC9A1 and acute myeloid leukemia.